Zymeworks Inc.

NasdaqGS:ZYME Voorraadrapport

Marktkapitalisatie: US$914.7m

Zymeworks Dividend

Dividend criteriumcontroles 0/6

Zymeworks does not have a record of paying a dividend.

Belangrijke informatie

n/a

Dividendrendement

-4.3%

Terugkoop Rendement

Totaal aandeelhoudersrendement-4.3%
Toekomstig dividendrendement0%
Dividendgroein/a
Volgende betaaldatum dividendn/a
Ex-dividenddatumn/a
Dividend per aandeeln/a
Uitbetalingsration/a

Recente dividendupdates

Geen updates

Recent updates

Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Nov 03
Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook

Nov 01
Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook

Zymeworks Approaching A Moment Of Truth With Zanidatamab

Sep 27

Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week

Aug 07
Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week

Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up

Jul 26
Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up

Zymeworks: A Somewhat Complicated Story

Jul 09

Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

Jun 12
Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

May 03
Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data

Apr 18

Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments

Mar 05

Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion

Feb 06

Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind

Jan 31

Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M

Nov 08

Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone

Oct 26

Zymeworks: A Roller Coaster Year

Jul 26

Zymeworks And The Blue Falcon Elucidation

May 17

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Insufficient data to determine if ZYME's dividends per share have been stable in the past.

Groeiend dividend: Insufficient data to determine if ZYME's dividend payments have been increasing.


Dividendrendement versus markt

Zymeworks Dividendrendement versus markt
Hoe verhoudt ZYME dividendrendement zich tot de markt?
SegmentDividendrendement
Bedrijf (ZYME)n/a
Markt onderkant 25% (US)1.5%
Markt Top 25% (US)4.5%
Gemiddelde industrie (Biotechs)2.2%
Analist prognose (ZYME) (tot 3 jaar)0%

Opmerkelijk dividend: Unable to evaluate ZYME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Hoog dividend: Unable to evaluate ZYME's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Winstuitkering aan aandeelhouders

Verdiendekking: Insufficient data to calculate ZYME's payout ratio to determine if its dividend payments are covered by earnings.


Contante uitbetaling aan aandeelhouders

Kasstroomdekking: Unable to calculate sustainability of dividends as ZYME has not reported any payouts.


Ontdek bedrijven met een sterk dividend